The Satiety Effect After Okara Compared to Porridge Eating
Launched by TEL-AVIV SOURASKY MEDICAL CENTER · Feb 24, 2010
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
This will be a single blind, cross-over design. Study population will include 10 subjects. The patients will be randomly assigned to receive one of two meals, 48 gram Okara or 40 gram (similar caloric value) semolina in two occasions (two visits). After the eating, the subject will stay in a closed room, without watch or any irritation. After three hours, the patient will fill a VAS questionnaire, and will get a standard meal. The meal will be weighed before and after.
Okara is a natural water extracted food grade soy product, contains approximately 35% protein (mfb), and about 43% of diet...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy volunteers
- • Age 20-65 years old
- • Written Informed Consent
- Exclusion Criteria:
- • History of gastro-intestinal surgery
- • On medication that may influence gastric emptying, or medication for weight loss
- • Patient on PPI treatment, H2 Blockers or medication for weight loss
- • Known allergies to soy
- • Pregnancy or breast-feeding
- • Smoking
- • Athletes
- • Metabolic syndrome or diabetes mellitus
- • Family history of metabolic syndrome or diabetes mellitus
- • Weight loss \> 2 kg during two months before the study
About Tel Aviv Sourasky Medical Center
Tel Aviv Sourasky Medical Center, a leading academic medical institution in Israel, is renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a multidisciplinary approach, the center integrates cutting-edge medical technology and evidence-based practices to enhance patient care and outcomes. Its robust infrastructure supports a diverse range of clinical studies, fostering collaboration among healthcare professionals, researchers, and industry partners. The center's dedication to research excellence and patient safety positions it as a key player in the global clinical research landscape, driving advancements in medical knowledge and treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tel Aviv, , Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials